阿法骨化醇联合利拉鲁肽治疗老年2型糖尿病并骨质疏松的临床效果  

Clinical efficacy of alfacalcidol combined with liraglutide in the treatment of T2DM with osteoporosis in the elderly

作　　者：李美蓉[1] 邓菊梅 李小婷[1] LI Meirong;DENG Jumei;LI Xiaoting(Department of Endocrinology,Jinjiang Municipal Hospital,Fujian,Jinjiang 362200,China)

机构地区：[1]福建省晋江市医院内分泌科,福建晋江362200

出　　处：《中国医药科学》2021年第17期113-116,共4页China Medicine And Pharmacy

摘　　要：目的探讨阿法骨化醇联合利拉鲁肽治疗老年2型糖尿病并骨质疏松的临床疗效及安全性。方法选取2019年1-6月福建省晋江市医院收治的120例老年2型糖尿病并骨质疏松患者作为研究对象。采用随机数字表法将其分为观察组与对照组,对照组60例在常规血糖控制基础上应用阿法骨化醇治疗,观察组60例则在常规血糖控制基础上联合应用阿法骨化醇及利拉鲁肽,对比两组治疗前后血糖水平、骨代谢相关指标以及治疗总有效率、不良反应发生率。结果治疗前两组血糖(FPG、2 hPG、HbA1c)、骨代谢(BALP、TRAP-5b)水平比较,差异无统计学意义(P>0.05),治疗后均较治疗前明显降低,差异有统计学意义(P<0.05),但观察组治疗后血糖及骨代谢指标均明显低于对照组,差异有统计学意义(P<0.05);观察组治疗总有效率明显高于对照组,差异有统计学意义(P<0.05),但两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论采用利拉鲁肽联合阿法骨化醇治疗老年2型糖尿病并骨质疏松疗效显著且可以有效改善患者血糖及骨质代谢状态,且联合用药不会增加不良反应发生风险,具有应用及推广价值。Objective To investigate the clinical efficacy and safety of alfacalcidol combined with liraglutide in the treatment of type 2 diabetes mellitus(T2DM)with osteoporosis in the elderly.Methods A total of 120 elderly patients with T2DM and osteoporosis admitted to our hospital from January to June 2019 were selected as the study subjects.They were divided into the observation group and the control group by using the random number table method.60 patients in the control group were treated with alfacalcidol on the basis of conventional blood glucose control,while 60 patients in the observation group were treated with alfacalcidol combined with liraglutide on the basis of conventional blood glucose control.The blood glucose level,bone metabolism-related indices,the total effective rate of treatment and the incidence of adverse reactions(ARs)before and after treatment were compared between the two groups.Results Before treatment,there were no statistically significant differences between the two groups in the levels of blood glucose including fasting plasma glucose(FPG),2-hour postprandial blood glucose(2 hPG)and hemoglobin A1c(HbA1c),and in the levels of bone metabolism including bone alkaline phosphatase(BALP)and tartrate-resistant acid phosphatase-5b(TRAP-5b)(P>0.05).After treatment,the above indices were all significantly lower than those before treatment,with statistically significant differences(P<0.05).The indices of blood glucose and bone metabolism in the observation group were significantly lower than those in the control group after treatment,with statistically significant differences(P<0.05).The total effective rate of treatment in the observation group was significantly higher than that in the control group,with statistically significant differences(P<0.05).However,there was no statistically significant difference between the two the groups in the incidence of ARs(P>0.05).Conclusion The application of liraglutide combined with alfacalcidol in the treatment of T2DM with osteoporosis in the elderly is signifi

关 键 词：阿法骨化醇 利拉鲁肽 老年2型糖尿病 骨质疏松 骨质代谢 

分 类 号：R587.2[医药卫生—内分泌] R580[医药卫生—内科学]